



A.MENARINI
PHARMACEUTICALS IRELAND LTD
Healthcare for Life

Patient Organisation Support Disclosure

Methodological Note

1. Introduction and Scope

This methodological note is intended to help readers understand how support from A. Menarini Pharmaceuticals Ireland Ltd (A. Menarini) to Patient Organisation (PO) (including patient and healthcare advocacy groups which are not disease specific) within Ireland have been collated and reported.

2. Definition of Support

A.Menarini may support POs, in line with the IPHA Code of Practice and internal Ethical Codes, in the following ways:

- Projects of joint interest, which may include direct and indirect support
- Once off funding for a specific project or meeting, usually financial support
- Contracted services where A.Menarini contract a PO to perform a service.

All support will be defined in a contract between both parties prior to the provision of support.

3. Patient Organisation Support categories and methodologies

The IPHA disclosure template prescribes the following categories of PO Support:

- Financial support
- Significant indirect support
- Non-financial support
- Contracted services

POs have relevant bona fides checked and are qualified under an in-house SOP before going to contract. The nature of the support given – direct or indirect - is detailed in terms of expectations of input from the PO and from A.Menarini. All contracts are signed before a project or donation can proceed.

4. Data Privacy

Patient Associations are contractually obliged to at all times comply with all data privacy law requirements including the Data Privacy Act of 1988 and 2003, the Data Protection Directive 95/46/EC and the General Data Protection Regulation (GDPR).

5. Financial Aspects

The following must be noted with regards to methodology and business decisions associated with the collection and disclosure of the support:

- Data gathering – Transfer data is collated using the company's in house finance and reporting systems
- Timing: A.Menarini PO disclosures correspond to the period to which the event occurred for which the PO payment is being made. Therefore, following the standard accrual accounting concept, i.e. a payment



A.MENARINI
PHARMACEUTICALS IRELAND LTD
Healthcare for Life

Patient Organisation Support Disclosure

Methodological Note

made in 2025 relating to an event in 2024 will not be included in the 2025 report. Similarly a payment in 2024 being a deposit for a 2025 event will be disclosed in the 2025 PO report.

- Currency: All PO supports are disclosed in Euro. Any payments incurred in other currencies are converted at the prevailing spot rates, corresponding to the cost to the company.
- VAT: Where applicable, VAT is included.
- Multi-year contracts: Transfers correspond to the payment amount and date. i.e. a 3-year contract with equal annual payments will be disclosed in 3 separate years.

6. Publication of report

Publication of data will be made on a report hosted on www.menarini.ie, updated by 30 June every year. The data will remain published for 3 years from the time of disclosure. A.Menarini are obliged to hold records for at least 5 years.

IR-MEN-41-2026

Date of Preparation: June 2026